Allopurinol-induced acquired von Willebrand syndrome

Submitted: 20 June 2023
Accepted: 6 October 2023
Published: 25 October 2023
Abstract Views: 1386
PDF: 111
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Acquired von Willebrand syndrome (AVWS) is a relatively infrequent but often overlooked finding when testing for von Willebrand factor (VWF) levels in a patient with mucocutaneous bleeding. Known causes include cardiovascular disorders, hematologic and solid tumors, autoimmune disorders, hypothyroidism, and drugs. An incoercible oral bleeding after a two-teeth removal in a patient with a mechanical aortic valve eventually raised suspicion about an AVWS that was confirmed through laboratory testing. Substitution therapy with an exogenous VWF factor was required to control the bleeding. Known causes of AVWS, including Heyde’s syndrome, were ruled out. VWF levels finally normalized two days after suspension of allopurinol, which the patient received for symptomatic hyperuricemia, leading to his complete recovery and early discharge without any other complications. AVWS is an underdiagnosed entity due to a lack of testing. Allopurinol has never been postured before as a possible etiology and should be evaluated when reaching a diagnosis.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Plaudit

Leebeek FWG, Eikenboom JCJ. Von Willebrand’s Disease. N Engl J Med 2016;375:2067-80. DOI: https://doi.org/10.1056/NEJMra1601561
Michiels JJ, Budde U, van der Planken M, et al. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 2001;14:401-36. DOI: https://doi.org/10.1053/beha.2001.0141
Shetty S, Kasatkar P, Ghosh K. Pathophysiology of acquired von Willebrand disease: a concise review. Eur J Haematol 2011;87:99-106. DOI: https://doi.org/10.1111/j.1600-0609.2011.01636.x
Langer AL, Connell NT. Acquired von Willebrand syndrome. Hematol/Oncol Clin N Ame 2021;35:1103-16. DOI: https://doi.org/10.1016/j.hoc.2021.07.005
Day RO, Graham GG, Hicks M, et al. Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol. Clin Pharmacokinet 2007;46:623-44. DOI: https://doi.org/10.2165/00003088-200746080-00001
Casonato A, Galletta E, Galvanin F, Daidone V. Von Willebrand disease type Vicenza: In search of a classification for the archetype of reduced von Willebrand factor survival. eJHaem 2021;2:340-8. DOI: https://doi.org/10.1002/jha2.196
Parida S. Clinical causality assessment for adverse drug reactions. Indian J Anaesth 2013;57:325-6. DOI: https://doi.org/10.4103/0019-5049.115608

How to Cite

Eirís, J., Suárez-Terrón, M., Granados, P., Martínez-Campuzano, D., Cid, A. R., Haya, S., & Bonanad, S. (2023). Allopurinol-induced acquired von Willebrand syndrome. Bleeding, Thrombosis and Vascular Biology, 2(4). https://doi.org/10.4081/btvb.2023.88